Bristol Myers Squibb has or is discontinuing Daklinza (daclatasvir) in countries where the product is no longer routinely prescribed or there are other therapeutic options available. Daklinza played a significant role in providing a new era of treatment, offering patients across the globe the potential for cure from chronic HCV infection. New Hepatitis C treatments have built on the safety and efficacy profile of Daklinza to offer shorter treatment durations and a reduced pill burden, and thus providing patients more options for a potential cure.
Following the lapse / withdrawal of the marketing authorization in each country, the patents in that country will also be allowed to lapse. In the interim period between the lapse / withdrawal of a marketing authorization and patent expiry, Bristol Myers Squibb will not enforce its Daklinza patents in that country. This policy is specific for Daklinza moving forward.